Hemoglobinopathy

3

Review clinical trials related to Hemoglobinopathy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

Background: Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells. SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant. Researchers want to know how long RBCs survive in people with SCD and other blood disorders before and after treatment compared to those who had a bone marrow transplant. Objective: To learn how long RBCs survive in the body in people with SCD and other blood disorders compared to those whose disease was cured with a bone marrow transplant. Eligibility: People aged 18 years or older with SCD or another inherited blood disorder. People whose SCD or blood disorder was cured with a bone marrow transplant are also needed. Design: Participants will be screened. They will have a physical exam with blood and urine tests. Participants will have about 7 tablespoons of blood drawn. In the lab, this blood will be mixed with a vitamin called biotin. Biotin sticks to the outside of RBCs. This process is called "biotin labeling of RBCs." The next day, the participant s own biotin-labeled RBCs will be returned to their bloodstream. Participants will return regularly to have smaller blood samples (about 2 teaspoons) drawn. These samples will be tested to detect the percentage of cells that have biotin labels. These visits may be every 2 weeks, 4 weeks, or some other interval. Participants will continue this schedule for up to 20 weeks or until biotin can no longer be detected....

Participants needed: 100
Trial details
Phase: Early Phase 1Age: 18-100Biological sex: AllType: InterventionalSponsor: National Heart, Lung, and Blood Institute (NHLBI)Updated: Feb 24, 2026Locations: 1
Eligibility criteria

Provision of signed and dated informed consent form [+6]

Consumption of biotin supplements or raw eggs within the last 30 days. [+7]

Status: Recruiting

A Long-term Follow-up Study in Patients Who Received BEAM-101

This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).

Participants needed: 50
Trial details
Age: 14-37Biological sex: AllType: ObservationalSponsor: Beam Therapeutics Inc.Updated: Jan 28, 2026Locations: 17
Eligibility criteria

Have received BEAM-101 in Study BTX-AUT-001 and are in the process of completing... [+1]

There are no exclusion criteria for this study.

Status: Recruiting

A Phase I Study of SNH-119014 in Healthy Volunteers

SNH-119014 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of SNH-119014 in the context of Phase 1 studies in healthy volunteers. The effects of food on the absorption of SNH-119014 will also be evaluated in healthy volunteers.

Participants needed: 96
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: ScinnoHub Pharmaceutical Co., Ltd.Updated: Jul 25, 2025Locations: 1
Eligibility criteria

Healthy male or female subjects; [+3]

History of or current clinically significant circulatory system, endocrine syste... [+24]